Leukocyte dysfunction and reduced CTLA-4 expression are associated with perianal Crohn’s disease
Clinical and Experimental Immunology · 2024
DOI: 10.1093/cei/uxae027 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical and Experimental Immunology, 2024. Verfasst von Murillo Duarte-Silva und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil. Hauptthemen laut MEDLINE: CTLA-4 Antigen, Crohn Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CAPES, CNPq, Fundação de Amparo à Pesquisa do Estado de São Paulo.
Abstract (Originalsprache)
Although perianal Crohn’s disease (PCD) is highly associated with the exacerbated inflammation, the molecular basis and immunological signature that distinguish patients who present a history of perianal lesions are still unclear. This paper aims to define immunological characteristics related to PCD. In this cross-sectional observational study, we enrolled 20 healthy controls and 39 CD patients. Blood samples were obtained for the detection of plasma cytokines and lipopolysaccharides (LPS). Peripheral blood mononuclear cells (PBMCs) were phenotyped by flow cytometry. Leukocytes were stimulated with LPS or anti-CD3/anti-CD28 antibodies. Our results show that CD patients had augmented plasma interleukin (IL)-6 and LPS. However, their PBMC was characterized by decreased IL-6 production, while patients with a history of PCD produced higher IL-6, IL-8, and interferon-γ, along with decreased tumor necrosis factor alpha (TNF). CD patients had augmented FoxP3 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulatory markers, though the PCD subjects presented a significant reduction in CTLA-4 expression. CTLA-4 as well as IL-6 and TNF responses were able to distinguish the PCD patients from those who did not present perianal complications. In conclusion, IL-6, TNF, and CTLA-4 exhibit a distinct expression pattern in CD patients with a history of PCD, regardless of disease activity. These findings clarify some mechanisms involved in the development of the perianal manifestations and may have a great impact on the disease management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
- Department of Clinical Analysis, Toxicology and Food Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.
- Department of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
- Department of Genetics and Evolution, Federal University of São Carlos, São Carlos, SP, Brazil.
ORCID-Profile: Murillo Duarte-Silva
Förderung
- CAPES
- CNPq
- Fundação de Amparo à Pesquisa do Estado de São Paulo
Zitieren
APA
Duarte-Silva, M., Parra, R. S., Feitosa, M. R., Nardini, V., Maruyama, S. R., da Rocha, J. J. R., Feres, O., & de Barros Cardoso, C. R. (2024). Leukocyte dysfunction and reduced CTLA-4 expression are associated with perianal Crohn’s disease. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxae027
Vancouver
Duarte-Silva M, Parra RS, Feitosa MR, Nardini V, Maruyama SR, da Rocha JJR, et al. Leukocyte dysfunction and reduced CTLA-4 expression are associated with perianal Crohn’s disease. Clinical and Experimental Immunology. 2024. doi:10.1093/cei/uxae027
BibTeX
@article{DuarteSilva2024,
author = {Duarte-Silva, Murillo and Parra, Rogério Serafim and Feitosa, Marley Ribeiro and Nardini, Viviani and Maruyama, Sandra Regina and da Rocha, José Joaquim Ribeiro and Feres, Omar and de Barros Cardoso, Cristina Ribeiro},
title = {Leukocyte dysfunction and reduced CTLA-4 expression are associated with perianal Crohn’s disease},
journal = {Clinical and Experimental Immunology},
year = {2024},
doi = {10.1093/cei/uxae027}
}
EUVIMED